Wall Street Zen Downgrades Seres Therapeutics (NASDAQ:MCRB) to Strong Sell

Key Points

• Wall Street Zen downgraded Seres Therapeutics from sell to strong sell, adding to a mixed analyst picture on the stock.
• Seres Therapeutics recently reported Q1 EPS of -$2.08, missing expectations by $0.20, while revenue came in line at $0.36 million.
• The stock was trading at $7.70, near its 52-week low of $6.53, and the company has a market cap of about $74.5 million.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on MCRB. Canaccord Genuity Group reiterated a "buy" rating and issued a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a "sell (d)" rating on shares of Seres Therapeutics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Seres Therapeutics currently has a consensus rating of "Hold" and an average price target of $22.00.

Seres Therapeutics Stock Down 0.3%

Shares of Seres Therapeutics stock opened at $7.70 on Friday. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $29.98. The business has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.05. The firm has a market cap of $74.54 million, a PE ratio of -1.49 and a beta of 0.12.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Seres Therapeutics by 37.5% during the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company's stock worth $214,000 after purchasing an additional 3,918 shares during the last quarter. 683 Capital Management LLC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $778,000. ExodusPoint Capital Management LP acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $190,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $214,000. Finally, Barclays PLC boosted its holdings in shares of Seres Therapeutics by 427.8% during the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company's stock worth $111,000 after purchasing an additional 6,024 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.